1016 ECP federation bio
BioCentury & Getty Images

Emerging Company Profile

Fed Bio: designing gut microbiomes with staying power and enhancing immune-modulating bacteria

Microbiome company emerges with $50M, lead program to treat hyperoxaluria with designed consortia

Microbiome company with Venrock, Stanford founders emerges with $50 million series A round and a lead program to treat hyperoxaluria with a designed microbiome able to persist in patients’ guts.

Oct 17, 2020 | 2:14 AM GMT

Fed Bio seeks to eliminate the need for repeated dosing of microbiome therapies for chronic diseases by designing complex bacterial communities that can stably colonize the gut.

The

Read the full 967 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE